title: Characterization of the interaction between tumor necrosis factor-stimulated gene-6 and heparin: implications for the inhibition of plasmin in extracellular matrix microenvironments.
abstract: TSG-6, the secreted product of tumor necrosis factor-stimulated gene-6, is not constitutively expressed but is up-regulated in various cell-types during inflammatory and inflammation-like processes. The mature protein is comprised largely of contiguous Link and CUB modules, the former binding several matrix components such as hyaluronan (HA) and aggrecan. Here we show that this domain can also associate with the glycosaminoglycan heparin/heparan sulfate. Docking predictions and site-directed mutagenesis demonstrate that this occurs at a site distinct from the HA binding surface and is likely to involve extensive electrostatic contacts. Despite these glycosaminoglycans binding to non-overlapping sites on the Link module, the interaction of heparin can inhibit subsequent binding to HA, and it is possible that this occurs via an allosteric mechanism. We also show that heparin can modify another property of the Link module, i.e. its potentiation of the anti-plasmin activity of inter-alpha-inhibitor (IalphaI). Experiments using the purified components of IalphaI indicate that TSG-6 only binds to the bikunin chain and that this is at a site on the Link module that overlaps the HA binding surface. The association of heparin with the Link module significantly increases the anti-plasmin activity of the TSG-6.IalphaI complex. Changes in plasmin activity have been observed previously at sites of TSG-6 expression, and the results presented here suggest that TSG-6 is likely to contribute to matrix remodeling, at least in part, through down-regulation of the protease network, especially in locations containing heparin/heparan sulfate proteoglycans. The differential effects of HA and heparin on TSG-6 function provide a mechanism for its regulation and functional partitioning in particular tissue microenvironments.
authors.affiliation: Medical Research Council Immunochemistry Unit, University of Oxford, United Kingdom.
authors.forename: David J
authors.initials: DJ
authors.lastname: Mahoney
authors.forename: Barbara
authors.initials: B
authors.lastname: Mulloy
authors.forename: Mark J
authors.initials: MJ
authors.lastname: Forster
authors.forename: Charles D
authors.initials: CD
authors.lastname: Blundell
authors.forename: Eric
authors.initials: E
authors.lastname: Fries
authors.forename: Caroline M
authors.initials: CM
authors.lastname: Milner
authors.forename: Anthony J
authors.initials: AJ
authors.lastname: Day
mesh_terms: D000510:Alpha-Globulins / Q000378:metabolism; D015815:Cell Adhesion Molecules / Q000235:genetics / Q000378:metabolism*; D005109:Extracellular Matrix / Q000378:metabolism*; D005341:Fibrinolysin / Q000037:antagonists & inhibitors*; D019812:Heparan Sulfate Proteoglycans / Q000378:metabolism; D006493:Heparin / Q000378:metabolism*; D006801:Humans; D006820:Hyaluronic Acid / Q000378:metabolism; D008958:Models, Molecular; D016297:Mutagenesis, Site-Directed; D011485:Protein Binding; D017434:Protein Structure, Tertiary
chemical_list: D000510:Alpha-Globulins; D015815:Cell Adhesion Molecules; D019812:Heparan Sulfate Proteoglycans; C072273:TNFAIP6 protein, human; C011877:inter-alpha-inhibitor; D006820:Hyaluronic Acid; D006493:Heparin; D005341:Fibrinolysin